Stock Analiz

MRNA vs ARGX stock comparison

Moderna vs. Argenx · data as of November 13, 2026

Moderna (MRNA) has a market value of about $90.4B, Argenx (ARGX) about $59.6B. Over their latest twelve months Moderna had revenue of $2.5B and Argenx $5.8B.

On our five checks Argenx scores higher: 2.4 out of 5 (weak) against 1.0 (weak).

By area, the stronger company is Argenx on future growth; Argenx on track record; Argenx on financial health.

Moderna leads on 1 of the compared lines and Argenx on 13.

Side by side

MRNAARGX
Size and price
Market cap$90.4B$59.6B
Share price$223.37$960.04
Score
Overall score (of 5)1.02.4
Value00
Future growth14
Track record12
Financial health25
Shareholder returns11
Valuation
P/E (TTM)—33.2
Forward P/E—31.5
Price / free cash flow—193.0
Price / sales35.810.2
EV / EBITDA—28.6
PEG——
DCF value vs. price—−72%
Business
Revenue$2.5B$5.8B
Net income-$2.8B$1.9B
Free cash flow-$2.0B$309M
Net margin-110.5%32.2%
Gross margin (5-yr avg.)59.9%90.8%
ROIC (5-yr avg.)9.4%-7.0%
Growth
Revenue growth (1 yr)-39.9%88.6%
Revenue growth (5 yrs, per year)19.3%130.8%
EPS growth (5 yrs, per year)——
Balance sheet and payouts
Net cash (cash minus debt)$3.9B$5.1B
Dividend yieldNoneNone
Shareholder yield0.0%0.0%
Analysts
Upside to average target−29%+19%
Consensus ratingHoldBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: MRNA TTM to September 30, 2026, ARGX TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Moderna or Argenx?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Argenx scores 2.4 out of 5 and Moderna 1.0; the table shows where each one is stronger.

Which grows faster, Moderna or Argenx?

Over five years Argenx grew revenue about 130.8% a year and Moderna about 19.3% a year.

Full Moderna analysis → Full Argenx analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.